Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Portfolio Pulse from
Xilio Therapeutics has provided updates on its pipeline and business, along with its Q4 and full-year 2024 financial results. The company anticipates additional Phase 2 data for vilastobart in combination with atezolizumab for MSS CRC patients by mid-2025.
March 11, 2025 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Xilio Therapeutics announced its 2024 financial results and pipeline updates, including expected Phase 2 data for vilastobart with atezolizumab in MSS CRC patients by mid-2025.
The announcement of financial results and pipeline updates, particularly the anticipated Phase 2 data, is likely to positively impact XLO's stock as it shows progress in their clinical trials and potential future developments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100